Welcome to our dedicated page for Zoetis SEC filings (Ticker: ZTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zoetis Inc. filings document the animal health company's operating results, capital returns, financing activity and governance disclosures. Recent 8-K reports furnish quarterly and annual financial results, guidance, dividend declarations, investor presentations and other Regulation FD disclosures.
The company's proxy materials address board and compensation matters, including executive pay and equity-award disclosures. Other filings record its New York Stock Exchange-listed common stock and debt financing, including a private offering of convertible senior notes, related indenture terms and capped call transactions.
Zoetis Inc. disclosed that it entered into an Underwriting Agreement on August 11, 2025 for a public debt offering of two senior note tranches. The company is issuing $850,000,000 aggregate principal amount of 4.150% Senior Notes due 2028 and $1,000,000,000 aggregate principal amount of 5.000% Senior Notes due 2035. These Notes are issued under Zoetis’s existing indenture with Deutsche Bank Trust Company Americas, as supplemented on August 18, 2025, and are registered under an effective Form S-3 shelf registration statement. Related agreements, indentures, note forms, and legal opinions are filed as exhibits.
Zoetis Inc. (ZTS) filed an automatic shelf registration statement on Form S-3 as a well-known seasoned issuer, enabling the company and future selling securityholders to issue an indeterminate amount of securities, including debt, common and preferred stock, warrants, depositary shares, purchase contracts/units, guarantees and hybrid instruments.
Each issuance will be detailed in a later prospectus supplement; no specific size, price or timing is disclosed in this filing. Net proceeds, when and if raised, may fund general corporate purposes such as working capital, capital expenditures, acquisitions and debt refinancing.
The prospectus summarises indenture terms—pari-passu ranking, optional redemption, covenants limiting certain liens and sale-leasebacks, standard events of default and defeasance options. The company re-confirms its NYSE listing (symbol “ZTS”) and notes 443.9 million common shares outstanding (authorised: 6 billion).
Risk factors are incorporated by reference and cover competitive pressures, supply-chain disruption, economic conditions, regulation, FX volatility and substantial indebtedness. The filing involves no immediate security issuance; it simply preserves capital-raising flexibility.
Zoetis (ZTS) Q2-25 10-Q highlights:
- Revenue rose 4.2% YoY to $2.46 bn; H1-25 up 2.8% to $4.68 bn.
- Net income climbed 15.1% YoY to $718 m; diluted EPS $1.61 vs $1.37. H1 EPS $3.02 (+13%).
- Gross margin improved to 73.6% (cost of sales down 2.8% despite higher volume).
- Operating expenses were mixed: SG&A +6.2%, R&D flat, amortization -6.3%. Restructuring & A&D costs fell to $30 m from $42 m.
- Effective tax rate 20.4% vs 20.0%.
- Segment trends: Companion animal +8.4% to $1.79 bn; Livestock -8.1% to $638 m. Strongest products: Parasiticides (+12%), Vaccines (+13%), Dermatology (+11%). Anti-infectives -17%.
- Cash $1.44 bn (-$552 m YTD) after $781 m buybacks and $447 m dividends. Debt unchanged at $6.65 bn; net debt up.
- Treasury shares outstanding 57.9 m; $4.9 bn remains on $6 bn repurchase authorization.
- Inventory rose 5.8% YoY to $2.44 bn; restructuring accrual $20 m.
- IRS audit could add up to $450 m tax liability; uncertain timing.
Overall, Zoetis delivered double-digit EPS growth driven by companion animal strength and margin expansion, while livestock softness, rising inventories and tax/audit uncertainties warrant monitoring.